Moderna Partners with Mexican Government for 10M-Dose Domestic Vaccine Production
Moderna signed a long-term agreement with the Mexican government to develop local mRNA manufacturing and transfer technology to Laboratorios Liomont for domestic COVID-19 vaccine production. The deal commits up to 10 million doses for Mexico’s 2025–26 campaign and bolsters the country’s pandemic preparedness.
1. Strategic Agreement Details
Moderna entered a long-term strategic agreement with the Mexican government under a Memorandum of Understanding to build a local mRNA ecosystem, support clinical research aligned with national health priorities and enhance the country’s pandemic preparedness framework.
2. Technology Transfer and Supply Commitments
The partnership includes technology transfer to Laboratorios Liomont for domestic manufacturing of Moderna’s COVID-19 vaccine, with a firm commitment to supply up to 10 million doses for Mexico’s 2025–26 vaccination campaign and expand access to its respiratory vaccine portfolio.
3. Stock Performance and Analyst Outlook
Moderna shares trade 2.9% below their 20-day SMA and 37.7% above the 100-day SMA following a 31.6% gain over the past year; RSI sits at 53.6 while MACD remains below its signal line. Analysts forecast Q4 EPS of -$2.60 on $638.9 million in revenue and maintain an average price target of $50.52 under a Hold consensus.